http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 06:29:14 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html <p>ThinkEquity analyst Ashok Kumar initiates coverage on Regentis Biomaterials Ltd. (NYSE: RGNT) with a Buy rating and a price target of $10.00.</p><p>The analyst comments "Regentis Biomaterials is a single-asset medtech advancing GelrinC for focal knee cartilage defects; GelrinV and GelrinP are optionality. We rate the shares BUY with a $10.00 price target because de-risking is underway: Europe has CE Mark approval with a partner-led http://www.streetinsider.com/New+Coverage/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html Mon, 02 Mar 2026 06:29:14 -0500 RGNT http://www.streetinsider.com/Analyst+Comments/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html <p>ThinkEquity analyst Ashok Kumar initiates coverage on Regentis Biomaterials Ltd. (NYSE: RGNT) with a Buy rating and a price target of $10.00.</p><p>The analyst comments "Regentis Biomaterials is a single-asset medtech advancing GelrinC for focal knee cartilage defects; GelrinV and GelrinP are optionality. We rate the shares BUY with a $10.00 price target because de-risking is underway: Europe has CE Mark approval with a partner-led http://www.streetinsider.com/Analyst+Comments/ThinkEquity+Starts+Regentis+Biomaterials+Ltd.+%28RGNT%29+at+Buy/26086381.html Mon, 02 Mar 2026 06:29:14 -0500 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/IPOs/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) completed its initial public offering of 1,250,000 ordinary shares at $8.00 per share, generating gross proceeds of $10 million before underwriting discounts and expenses, according to a company statement.</p> <p>The Israel-based regenerative medicine company's shares began trading on the NYSE American on December 4, 2025, under the ticker symbol "RGNT." The company also granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments.</p> <p>Regentis plans to use the net proceeds primarily for development activities, including completion of its pivotal trial and preparation of a PMA submission for GelrinC, its lead product http://www.streetinsider.com/Equity+Offerings/Regentis+Biomaterials+completes+%2410+million+initial+public+offering/25706401.html Fri, 05 Dec 2025 16:10:09 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Press+Releases/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html <p align="justify">Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day http://www.streetinsider.com/Globe+Newswire/Regentis+Biomaterials+Ltd.+Announces+Closing+of+Initial+Public+Offering/25706396.html Fri, 05 Dec 2025 16:10:00 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+prices+IPO+at+%248+per+share%2C+raising+%2410+million/25696937.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) priced its initial public offering at $8.00 per ordinary share, the Israel-based regenerative medicine company announced. The offering consists of 1,250,000 ordinary shares, generating gross proceeds of $10 million before underwriting discounts and expenses.</p> <p>The company granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments. ThinkEquity serves as the sole book-running manager for the offering.</p> <p>Trading on the NYSE American is expected to begin December 4, 2025, under the ticker symbol "RGNT." The offering is scheduled to close on or about December 5, 2025, subject to customary closing conditions.</p> <p>Regentis plans http://www.streetinsider.com/IPOs/Regentis+Biomaterials+prices+IPO+at+%248+per+share%2C+raising+%2410+million/25696937.html Wed, 03 Dec 2025 19:23:35 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+prices+IPO+at+%248+per+share%2C+raising+%2410+million/25696937.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) priced its initial public offering at $8.00 per ordinary share, the Israel-based regenerative medicine company announced. The offering consists of 1,250,000 ordinary shares, generating gross proceeds of $10 million before underwriting discounts and expenses.</p> <p>The company granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments. ThinkEquity serves as the sole book-running manager for the offering.</p> <p>Trading on the NYSE American is expected to begin December 4, 2025, under the ticker symbol "RGNT." The offering is scheduled to close on or about December 5, 2025, subject to customary closing conditions.</p> <p>Regentis plans http://www.streetinsider.com/IPOs/Regentis+Biomaterials+prices+IPO+at+%248+per+share%2C+raising+%2410+million/25696937.html Wed, 03 Dec 2025 19:23:35 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT http://www.streetinsider.com/IPOs/Regentis+Biomaterials+prices+IPO+at+%248+per+share%2C+raising+%2410+million/25696937.html <p>Regentis Biomaterials Ltd. (NYSE American: RGNT) priced its initial public offering at $8.00 per ordinary share, the Israel-based regenerative medicine company announced. The offering consists of 1,250,000 ordinary shares, generating gross proceeds of $10 million before underwriting discounts and expenses.</p> <p>The company granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments. ThinkEquity serves as the sole book-running manager for the offering.</p> <p>Trading on the NYSE American is expected to begin December 4, 2025, under the ticker symbol "RGNT." The offering is scheduled to close on or about December 5, 2025, subject to customary closing conditions.</p> <p>Regentis plans http://www.streetinsider.com/IPOs/Regentis+Biomaterials+prices+IPO+at+%248+per+share%2C+raising+%2410+million/25696937.html Wed, 03 Dec 2025 19:23:35 -0500 A.04832063 A.19657706 O.13817872 O.36250936 RGNT